| Literature DB >> 30657653 |
Anita E M Kneppers1, Roy A M Haast2,3, Ramon C J Langen1, Lex B Verdijk4, Pieter A Leermakers1, Harry R Gosker1, Luc J C van Loon4, Mitja Lainscak5,6, Annemie M W J Schols1.
Abstract
BACKGROUND: Pulmonary rehabilitation (PR) is a cornerstone in the management of chronic obstructive pulmonary disease (COPD), targeting skeletal muscle to improve functional performance. However, there is substantial inter-individual variability in the effect of PR on functional performance, which cannot be fully accounted for by generic phenotypic factors. We performed an unbiased integrative analysis of the skeletal muscle molecular responses to PR in COPD patients and comprehensively characterized their baseline pulmonary and physical function, body composition, blood profile, comorbidities, and medication use.Entities:
Keywords: Chronic obstructive pulmonary disease; Cluster analysis; Exercise training; Muscle plasticity; Peripheral muscle dysfunction
Mesh:
Year: 2019 PMID: 30657653 PMCID: PMC6463471 DOI: 10.1002/jcsm.12370
Source DB: PubMed Journal: J Cachexia Sarcopenia Muscle ISSN: 2190-5991 Impact factor: 12.910
Baseline subject characteristics
| Whole group | Cluster 1 | Cluster 2 |
| |
|---|---|---|---|---|
|
|
|
| ||
| Demographics | ||||
| Age, years | 64 ± 1 | 64 ± 2 | 65 ± 2 | ns |
| Sex, m/f (% male) | 37/14 (73) | 21/8 (72) | 11/5 (69) | ns |
| Smoking status | <0.1 | |||
| Current, | 44 (88) | 24 (83) | 16 (100) | |
| Former, | 6 (12) | 5 (17) | 0 (0) | |
| Completion of PR | ns | |||
| Without exacerbation, | 39 (76) | 23 (79) | 11 (69) | |
| With exacerbation, | 12 (24) | 6 (21) | 5 (31) | |
| Pulmonary function | ||||
| FEV1, % predicted | 34 [26–41] | 34 [26–41] | 38 [29–44] | ns |
| FVC, % predicted | 79 ± 3 | 80 ± 3 | 77 ± 5 | ns |
| FEV1/FVC, % | 33 [26–42] | 31 [26–40] | 33 [28–46] | ns |
| Physical function | ||||
| 6MWT, m | 344.68 ± 15.44 | 352.59 ± 22.11 | 348.00 ± 20.94 | ns |
| Peak load, W | 62.96 ± 3.30 | 62.81 ± 4.81 | 65.20 ± 5.51 | ns |
| Peak VO2, mL/kg/min | 11.75 ± 0.58 | 12.31 ± 0.85 | 11.35 ± 0.77 | ns |
| Body composition | ||||
| BMI, kg/m2 | 24.8 ± 0.6 | 24.2 ± 0.7 | 25.5 ± 1.3 | ns |
| FMI, kg/m2 | 7.8 ± 0.3 | 7.4 ± 0.4 | 8.3 ± 0.7 | ns |
| FFMI, kg/m2 | 16.9 ± 0.4 | 16.7 ± 0.5 | 16.9 ± 0.9 | ns |
| ASMI, kg/m2 | 6.6 ± 0.2 | 6.5 ± 0.2 | 6.9 ± 0.4 | ns |
| Muscle mass depletion, | 30 (60) | 20 (69) | 7 (47) | ns |
| Blood profile | ||||
| Triglycerides, mmol/L | 1.28 ± 0.08 | 1.16 ± 0.10 | 1.46 ± 0.14 | <0.1 |
| HDL cholesterol, mmol/L | 1.77 ± 0.09 | 1.80 ± 0.10 | 1.73 ± 0.16 | ns |
| LDL cholesterol, mmol/L | 3.01 ± 0.15 | 2.77 ± 0.19 | 3.25 ± 0.26 | ns |
| LDL/HDL, ratio | 1.94 ± 0.14 | 1.65 ± 0.14 | 2.21 ± 0.27 | <0.1 |
| HOMA‐IR | 3.40 [1.80–6.70] | 3.70 [1.95–5.75] | 2.90 [1.85–8.00] | ns |
| Comorbidities | ||||
| Long‐term oxygen therapy, | 20 (39) | 11 (38) | 5 (31) | ns |
| Heart failure, | 8 (16) | 5 (17) | 2 (13) | ns |
| Ischemic heart disease, | 4 (8) | 3 (10) | 0 (0) | ns |
| Atrial fibrillation, | 1 (2) | 1 (3) | 0 (0) | ns |
| Arterial hypertension, | 21 (41) | 10 (34) | 8 (50) | ns |
| Cholesterolaemia, | 14 (27) | 6 (21) | 5 (31) | ns |
| Type 2 diabetes mellitus, | 7 (14) | 5 (17) | 1 (6) | ns |
6MWT, 6 min walk test; ASMI, appendicular skeletal muscle mass index; BMI, body mass index; FEV1, forced expiratory volume in 1 s; FFMI, fat‐free mass index; FMI, fat mass index; FVC, forced vital capacity; HDL, high‐density lipoprotein; HOMA‐IR, homeostatic model of insulin resistance; IQR, interquartile range; LDL, low‐density lipoprotein; PR, pulmonary rehabilitation. Due to the insufficient sample size, individual values for Cluster 3 (n = 4) and Cluster 4 (n = 2) are not depicted in this table. Data expressed as mean ± SEM unless indicated otherwise.
Significance of between group (Cluster 1 vs. Cluster 2) comparisons assessed by independent sample t‐test, Mann–Whitney U‐test, or χ2 test.
Median [IQR].
Figure 1Molecular network and network‐constrained hierarchical clustering of molecular rehabilitation responses. (A) Network‐constrained clusters revealing eight distinct processes (P), as indicated with different colours. (B) Molecular rehabilitation responses. The literature‐based molecular network is indicated as lines between molecular markers. Circles represent mRNA markers; pentagons represent protein markers. Numbers correspond to individual markers as depicted in Supporting Information, .
Figure 2Hierarchical clustering of patients. (A) Silhouette scores for n clusters (mean ± SEM). Clustering based on raw molecular rehabilitation responses (marker values; i.e. no data reduction) is indicated in grey; clustering based on eight process scores is indicated in black. (B) Patients individual silhouette coefficient values per cluster. (c) Dendrogram and clustered heatmap of individual marker rehabilitation responses (Z‐scores) and process scores.
Figure 3Associations between molecular rehabilitation responses. Each square displays a scatter plot and regression line of the processes indicated on the x and y axis, for both Cluster 1 and Cluster 2. Differences between correlations were tested by a Fisher's r‐to‐z transformation and indicated with a red outline (P < 0.05) or orange outline (P < 0.1). Pearson correlation coefficients per cluster are depicted for differential correlations and when P < 0.1. # P < 0.1, * P < 0.05, ** P < 0.01, *** P < 0.001.
Figure 4Functional rehabilitation responses per cluster. Individual rehabilitation‐induced changes. (A) Distance (metres) walked in 6 min walk test (6MWT), n = 28/15. (B) Peak load (W) on a cycle ergometer test, n = 23/14. Data expressed as mean ± SD. (C) Percentage of patients with a change in 6MWT, peak load, or both, exceeding the minimal clinically important difference (MCID; 6MWT: 25 m, peak load: 10 W). * P < 0.05, ** P < 0.01, *** P < 0.001, indicating significance of within‐group rehabilitation responses or significance of differences between indicated groups.